• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Zealand Pharma (CPSE:ZEAL)'s Phase 1 Safety Results Mean For Shareholders

    Simply Wall St·10/28/2026 08:14:44
    Listen to the news
    • Zealand Pharma reported that its Kv1.3 ion channel blocker ZP9830 was safe and well tolerated in a completed Phase 1 multiple ascending dose study in healthy volunteers, supporting longer treatment evaluation and a follow up Phase 1b trial in plaque psoriasis.
    • The focus on Kv1.3, which is selectively expressed on effector memory T cells, points to potential diversification for Zealand Pharma into immune mediated inflammatory diseases beyond its obesity and metabolic pipeline.
    • The next consideration is how Zealand Pharma's investment narrative around pipeline balance and partnership reliance may be influenced by ZP9830's Phase 1 safety profile.

    Scan how Zealand Pharma's push into immune mediated diseases compares with other hand picked healthcare names with resilient balance sheets by reviewing our list of solid balance sheet and fundamentals (207 results).

    Zealand Pharma Investment Narrative Recap

    To own Zealand Pharma, you need to buy into a story where obesity and metabolic partnerships remain the financial anchor, while earlier immune mediated assets add optionality without overwhelming cash needs. The ZP9830 data fits that view. It broadens the scientific footprint but does not change that near term attention still sits on petrelintide, survodutide and royalty streams.

    The short term swing factor is still upcoming obesity trial readouts and how those feed into milestones, given analyst expectations for falling revenue and earnings. The biggest operational risk remains trial setbacks or weak differentiation in obesity, which could matter more to the business than early psoriasis data from ZP9830.

    The most relevant development here is the completed first in human SAD and MAD work on ZP9830, together with a move into Phase 1b in plaque psoriasis. Four weeks of multiple dosing in healthy volunteers with only mild, non serious adverse events keeps the immune program alive without adding obvious new safety questions to the wider story.

    For you as a shareholder, that matters mainly as a secondary catalyst. The immune franchise could, over time, help offset the dependence on partner milestones in obesity and metabolic disease if later trials go well. Execution risk remains high at this stage, so portfolio balance and cash use around the core metabolic pipeline still set the tone for Zealand Pharma.

    What The Current Forecasts Imply For Zealand Pharma

    Analysts currently model a sharp reset for Zealand Pharma's financial profile. Consensus points to revenue declining by 25.8% a year over the next three years, while longer range estimates assume earnings could shift from DKK 2.7b today to DKK 367.5m by 2029 if margins move toward the broader biotech peer group.

    That earnings path implies a value drop of about DKK 2.3b from current earnings to the 2029 consensus figure. This frames how much cash generation would need to compress before potentially rebuilding from a lower base. Forecasts also lean on a modest reduction in share count of 1.27% per year, which slightly supports earnings per share even as total profit is expected to step down.

    On the top line, the same 2029 scenario assumes Zealand Pharma generates DKK 1.9b of revenue, with profit of DKK 367.5m in that year. To reconcile those outputs with the current analyst price target, the stock would have to trade on a P/E of 89.4x those 2029 earnings, compared with 6.7x today and 15.2x for the wider US biotech sector.

    Zealand Pharma's narrative projects DKK 1.9b revenue and DKK 367.5m earnings by 2029. This rests on revenue declining 25.8% a year and an earnings decrease of about DKK 2.3b from DKK 2.7b today.

    Uncover why Zealand Pharma's fair value indicates an 84% potential upside to its current price that could narrow quickly.

    CPSE:ZEAL 1-Year Stock Price Chart
    CPSE:ZEAL 1-Year Stock Price Chart

    Exploring Other Perspectives

    You might see these ZP9830 results as a helpful extra, yet the most cautious analysts focus on a different pressure point. They worry about petrelintide converting to real world use, with some modelling revenue falling 66.9% a year and earnings near DKK 32.1m by 2029. Those forecasts were set before today’s immune data, so you may want to compare several viewpoints and decide which story feels more realistic to you.

    Explore 2 other Zealand Pharma fair value estimates, including one that suggests it could be worth just DKK396.00!

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Zealand Pharma?

    Once you have a handle on Zealand Pharma, it can help to set it alongside a few different types of opportunities so your portfolio is not leaning on a single story.

    • If you want potential upside in smaller companies, scan through 124 elite penny stocks with strong financials that already show stronger financial underpinnings than many of their peers.
    • For investors who care most about price versus fundamentals, compare Zealand Pharma with 195 high quality undervalued stocks that combine resilient cash flows with solid balance sheets.
    • If steadier income matters to you, weigh the Zealand Pharma thesis against 224 dividend fortresses that offer higher yields while still aiming for durability of payouts.